Slope (Healthcare Technology Systems) key facts
- Provider of biospecimen lifecycle software, data, and services for clinical trials.
- Slope (Healthcare Technology Systems)’s last known valuation is $89.0M.
- It has raised $37.9M; the latest was Later Stage VC ($14.0M) in Aug 2024.
- Notable investors include Alumni Ventures, New Enterprise Associates, GrowthX Capital, Breyer Capital, Eniac Ventures — 16 tracked in total.
- Status: Privately Held (backing).
Who backs Slope (Healthcare Technology Systems)
16+- ·The complete investor list: 16 names
- ·Watch Slope (Healthcare Technology Systems): the Monday email on marks, rounds and moves
Slope (Healthcare Technology Systems) funding rounds
No funding rounds for Slope (Healthcare Technology Systems) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Slope (Healthcare Technology Systems) valuation
Slope (Healthcare Technology Systems)'s last known valuation is $89 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Slope (Healthcare Technology Systems) investors
16 investors are on record for Slope (Healthcare Technology Systems), including Alumni Ventures, New Enterprise Associates, GrowthX Capital and Breyer Capital. By type, the record holds 7 venture capital firms.
About Slope (Healthcare Technology Systems)
Provider of biospecimen lifecycle software, data, and services for clinical trials. The company's core offering, Biospecimen360™ (B360™), is a vendor-agnostic software that orchestrates the entire biospecimen lifecycle, enabling bi-directional data exchange across sites, labs, LIMS, and EDC, as well as centralized sample tracking.
- Sector
- Healthcare
- HQ
- Norfolk, VA, United States
- Founded
- 2016
- Employees
- 57
- Website
- slopeclinical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Slope (Healthcare Technology Systems)’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.